Regenerative Medical Technology (RMTG) Common Equity (2017 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Common Equity of -$35.6 million for Q1 2026, down 26.69% year-over-year from -$48.6 million in Q1 2025, and down 2.52% quarter-over-quarter from -$34.7 million in Q4 2025.
Regenerative Medical Technology (RMTG) Common Equity (2017 - 2026) Analysis & Trends
Regenerative Medical Technology's Common Equity history runs 10 years deep, the most recent figure standing at -$35.6 million for Q1 2026.
- In Q1 2026, Common Equity fell 26.69% year-over-year to -$35.6 million; the TTM figure through Mar 2026 stood at -$35.6 million (down 26.69% YoY), while the FY2025 annual figure was -$34.7 million, down 27.01% from the prior year.
- Common Equity for Q1 2026 stood at -$35.6 million, down from -$34.7 million in the prior quarter.
- The five-year high for Common Equity was -$8.2 million in Q1 2022, with the low at -$35.6 million in Q1 2026.
- The 5-year median for Common Equity is -$23.8 million (2024), against an average of -$22.1 million.
- The sharpest annual moves came in 2022 and 2025: Common Equity tumbled 492.9% in 2022, then dropped 12.34% in 2025.
- Regenerative Medical Technology's Common Equity stood at -$12.0 million in 2022, then plunged by 81.9% to -$21.8 million in 2023, then slipped by 25.52% to -$27.4 million in 2024, then declined by 27.01% to -$34.7 million in 2025, then retreated by 2.52% to -$35.6 million in 2026.
- Business Quant data shows RMTG's Common Equity at -$35.6 million in Q1 2026, -$34.7 million in Q4 2025, and -$30.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 9.79 Bn |
| 10 | Regenerative Medical Technology | 656,948.41 | -404,499.59 | 1.77 Mn | -35.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.62 Mn |
| Dec 31, 2025 | -34.75 Mn |
| Sep 30, 2025 | -30.05 Mn |
| Jun 30, 2025 | -29.02 Mn |
| Mar 31, 2025 | -28.12 Mn |
| Dec 31, 2024 | -27.36 Mn |
| Sep 30, 2024 | -26.72 Mn |
| Jun 30, 2024 | -25.83 Mn |
| Mar 31, 2024 | -23.76 Mn |
| Dec 31, 2023 | -21.80 Mn |
| Sep 30, 2023 | -21.54 Mn |
| Jun 30, 2023 | -15.68 Mn |
| Mar 31, 2023 | -13.65 Mn |
| Dec 31, 2022 | -11.98 Mn |
| Sep 30, 2022 | -11.00 Mn |
| Jun 30, 2022 | -11.00 Mn |
| Mar 31, 2022 | -8.17 Mn |
| Dec 31, 2021 | -6.76 Mn |
| Sep 30, 2021 | -5.51 Mn |
| Jun 30, 2021 | -1.86 Mn |